TNFR2 Activator Biomarker Testing for Autoimmune Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for autoimmune diseases, such as type 1 diabetes, do not consistently produce beneficial outcomes in all subjects, necessitating a need for methods to accurately identify which subjects are likely to respond to treatments before administering them.
Innovation Solution
A method involving contacting an in vitro biological sample of CD8+ T cells from a subject with a TNFR2 activator and measuring CD8 protein density on autoreactive CD8+ T cells, where reduced density indicates a subject is likely to respond to treatment, and detecting C-peptide levels to confirm responsiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies for autoimmune diseases are administered, then treatment is provided to subjects, but beneficial outcomes are not consistently produced in all subjects
Solution Approach 1:
The patent applies preliminary action by conducting predictive biomarker testing before administering TNFR2 activator therapy. Specifically, the method measures CD8 protein density on autoreactive CD8+ T cells in vitro prior to treatment initiation. Subjects with reduced CD8 protein density are identified as likely responders before therapy begins, allowing selective treatment administration to improve reliability of beneficial outcomes while accounting for individual response variability.
2Adaptability or versatility
If treatment is administered to all subjects, then broad coverage is achieved, but identification of responsive subjects is not possible
Solution Approach 1:
The patent implements feedback by using in vitro measurement of CD8 protein density on autoreactive T cells as a predictive biomarker. This feedback mechanism provides advance information about subject responsiveness before treatment begins. The measured CD8 protein density serves as a feedback signal that guides treatment decisions, enabling identification of subjects likely to respond beneficially while maintaining broad coverage through objective criteria.
3Measurement precision
If predictive biomarker testing is implemented, then subject responsiveness can be identified, but additional testing steps are required
Solution Approach 1:
The patent applies the taking out principle by extracting and measuring a specific biomarker characteristic (CD8 protein density) from the complex immune cell population. Rather than requiring comprehensive analysis of all immune parameters, the method isolates and measures this single predictive biomarker on autoreactive CD8+ T cells. This extraction approach achieves precise responsiveness detection while simplifying the testing procedure to a focused measurement rather than complex multi-parameter analysis.
Data Source
AI summary
The invention features methods of identifying a subject having an autoimmune disease, such as type 1 diabetes, as likely to respond to treatment with a tumor necrosis factor-α (TNF-α) receptor II activator. The method involves measuring CD8 protein density on the surface of autoreactive CD8+ T cells and identifying the subject as likely to respond to the treatment if the CD8 protein density is reduced relative to a reference CD8+ T cell. For type 1 diabetes, the method may involve measuring C-peptide levels in an in vitro biological sample from the subject, identifying the subject as likely to respond to the treatment if the C-peptide levels are detectable, and identifying the subject as unlikely to respond to the treatment if the C-peptide are substantially undetectable. The invention also features pharmaceutical compositions of one or more TNFR2 activators for use in treating an autoimmune disease in a subject identified as likely to respond to the treatment prior to the treating by according to the methods of the invention.